These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1203 related articles for article (PubMed ID: 33571745)

  • 21. Understanding the immunological aspects of SARS-CoV-2 causing COVID-19 pandemic: A therapeutic approach.
    Das A; Roy S; Swarnakar S; Chatterjee N
    Clin Immunol; 2021 Oct; 231():108804. PubMed ID: 34303849
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inflammasomes and SARS-CoV-2 Infection.
    Kaivola J; Nyman TA; Matikainen S
    Viruses; 2021 Dec; 13(12):. PubMed ID: 34960782
    [TBL] [Abstract][Full Text] [Related]  

  • 23. On the road to ending the COVID-19 pandemic: Are we there yet?
    Case JB; Winkler ES; Errico JM; Diamond MS
    Virology; 2021 May; 557():70-85. PubMed ID: 33676349
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Passive Immunity for Coronavirus Disease 2019: A Commentary on Therapeutic Aspects Including Convalescent Plasma.
    Lindholm PF; Ramsey G; Kwaan HC
    Semin Thromb Hemost; 2020 Oct; 46(7):796-803. PubMed ID: 32526774
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of Immune Response between SARS, MERS, and COVID-19 Infection, Perspective on Vaccine Design and Development.
    Ansariniya H; Seifati SM; Zaker E; Zare F
    Biomed Res Int; 2021; 2021():8870425. PubMed ID: 33564683
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination of a Sindbis-SARS-CoV-2 Spike Vaccine and αOX40 Antibody Elicits Protective Immunity Against SARS-CoV-2 Induced Disease and Potentiates Long-Term SARS-CoV-2-Specific Humoral and T-Cell Immunity.
    Scaglione A; Opp S; Hurtado A; Lin Z; Pampeno C; Noval MG; Thannickal SA; Stapleford KA; Meruelo D
    Front Immunol; 2021; 12():719077. PubMed ID: 34394127
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SARS-CoV-2 will constantly sweep its tracks: a vaccine containing CpG motifs in 'lasso' for the multi-faced virus.
    Oberemok VV; Laikova KV; Yurchenko KA; Marochkin NA; Fomochkina II; Kubyshkin AV
    Inflamm Res; 2020 Sep; 69(9):801-812. PubMed ID: 32656668
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19.
    Sharma O; Sultan AA; Ding H; Triggle CR
    Front Immunol; 2020; 11():585354. PubMed ID: 33163000
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
    Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
    Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
    Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development.
    Alturki SO; Alturki SO; Connors J; Cusimano G; Kutzler MA; Izmirly AM; Haddad EK
    Front Immunol; 2020; 11():1880. PubMed ID: 32973779
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?
    Lu L; Zhang H; Zhan M; Jiang J; Yin H; Dauphars DJ; Li SY; Li Y; He YW
    Sci China Life Sci; 2020 Dec; 63(12):1833-1849. PubMed ID: 33355886
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Deciphering the Role of Humoral and Cellular Immune Responses in Different COVID-19 Vaccines-A Comparison of Vaccine Candidate Genes in Roborovski Dwarf Hamsters.
    Trimpert J; Herwig S; Stein J; Vladimirova D; Adler JM; Abdelgawad A; Firsching TC; Thoma T; Sehouli J; Osterrieder K; Gruber AD; Sawitzki B; Sander LE; Cichon G
    Viruses; 2021 Nov; 13(11):. PubMed ID: 34835096
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments.
    Canedo-Marroquín G; Saavedra F; Andrade CA; Berrios RV; Rodríguez-Guilarte L; Opazo MC; Riedel CA; Kalergis AM
    Front Immunol; 2020; 11():569760. PubMed ID: 33362758
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dendritic cells in COVID-19 immunopathogenesis: insights for a possible role in determining disease outcome.
    Borges RC; Hohmann MS; Borghi SM
    Int Rev Immunol; 2021; 40(1-2):108-125. PubMed ID: 33191813
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peritoneal Administration of a Subunit Vaccine Encapsulated in a Nanodelivery System Not Only Augments Systemic Responses against SARS-CoV-2 but Also Stimulates Responses in the Respiratory Tract.
    Jearanaiwitayakul T; Apichirapokey S; Chawengkirttikul R; Limthongkul J; Seesen M; Jakaew P; Trisiriwanich S; Sapsutthipas S; Sunintaboon P; Ubol S
    Viruses; 2021 Nov; 13(11):. PubMed ID: 34835008
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunological Aspects of SARS-CoV-2 Infection and the Putative Beneficial Role of Vitamin-D.
    Peng MY; Liu WC; Zheng JQ; Lu CL; Hou YC; Zheng CM; Song JY; Lu KC; Chao YC
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34065735
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2.
    Tostanoski LH; Gralinski LE; Martinez DR; Schaefer A; Mahrokhian SH; Li Z; Nampanya F; Wan H; Yu J; Chang A; Liu J; McMahan K; Ventura JD; Dinnon KH; Leist SR; Baric RS; Barouch DH
    J Virol; 2021 Nov; 95(23):e0097421. PubMed ID: 34523968
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune Evasive Effects of SARS-CoV-2 Variants to COVID-19 Emergency Used Vaccines.
    Zhang Y; Banga Ndzouboukou JL; Gan M; Lin X; Fan X
    Front Immunol; 2021; 12():771242. PubMed ID: 34880867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 61.